Patients who take phosphate binders may be at a 22% higher risk of death that those who take other non-calcium based treatments.
The management of chronic kidney disease-mineral bone disorder (CKD-MBD) is central to the care of patients with kidney disease.
Chitosan gum could offer dialysis patients an inexpensive way to control phosphorus nonsystemically without adding to their daily pill burden.
In a study, nurses and technicians educated groups of hemodialysis patients about phosphate binders.
Researchers tested an intervention that included an educational fair, phosphorus group social, and staff education on phosphate binders.
Researchers observed reduced phosphorus levels in HD patients whose diet restricted intake of phosphorus additives.
Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Calcium-based and non-calcium-based binder use were associated with similar death risks.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Vascular calcification contributes to increased cardiovascular risk in dialysis patients.
New findings are consistent with those from previous animal studies.
PA21 comparable in safety and efficacy to sevelamer carbonate out to 52 weeks, study finds.
Serum levels vary throughout the day, and higher phosphorus intake exaggerates the early afternoon rise in serum phosphorus.
New findings raise questions "on the generalizability of previous research studies to the clinic setting," researchers conclude.
Low phosphorus increases all-cause and cardiovascular mortality only among the elderly.
Phosphorus levels are lower in postmenopausal women on estrogen replacement therapy.
Use of the agents is associated with a 29% and 22% decreased risk of all-cause and cardiovascular mortality.